Platelet aggregation and serum adenosine deaminase (ADA) activity in pregnancy associated with diabetes, hypertension and HIV

• Published in: Cell biochemistry and function Vol. 34; no. 5; pp. 343 - 350
• Main Authors: Leal, Claudio A. M., Leal, Daniela B. R., Adefegha, Stephen A., Morsch, Vera M., da Silva, José E. P., Rezer, João F. P., Schrekker, Clarissa M. L., Abdalla, Faida H., Schetinger, Maria R. C.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01-07-2016; Wiley Subscription Services, Inc
• Subjects: adenosine deaminase; Adenosine Deaminase - blood; Adenosine Diphosphate - pharmacology; Adult; Blood Coagulation - drug effects; Case-Control Studies; diabetes mellitus; Diabetes, Gestational - blood; Enzyme Assays; Female; HIV Infections - blood; HIV Infections - complications; Human immunodeficiency virus; Humans; hypertension; Hypertension - blood; Hypertension - complications; Lentivirus; platelet aggregation; Platelet Aggregation - drug effects; Platelet-Rich Plasma - metabolism; Pregnancy; human immunodeficiency virus; diabetes mellitus; hypertension; adenosine deaminase; pregnancy; platelet aggregation
• ISSN: 0263-6484; 1099-0844
• DOI: 10.1002/cbf.3197

Platelet aggregation and adenosine deaminase (ADA) activity were evaluated in pregnant women living with some disease conditions including hypertension, diabetes mellitus and human immunodeficiency virus infection. The subject population is consisted of 15 non‐pregnant healthy women [control group (CG)], 15 women with normal pregnancy (NP), 7 women with hypertensive pregnancy (HP), 10 women with gestational diabetes mellitus (GDM) and 12 women with human immunodeficiency virus‐infected pregnancy (HIP) groups. The aggregation of platelets was checked using an optical aggregometer, and serum ADA activity was determined using the colorimetric method. After the addition of 5 µM of agonist adenosine diphosphate, the percentage of platelet aggregation was significantly (p < 0·05) increased in NP, HP, GDM and HIP groups when compared with the CG, while the addition of 10 µM of the same agonist caused significant (p < 0·05) elevations in HP, GDM and HIP groups when compared with CG. Furthermore, ADA activity was significantly (p < 0·05) enhanced in NP, HP, GDM and HIP groups when compared with CG. In this study, the increased platelet aggregation and ADA activity in pregnancy and pregnancy‐associated diseases suggest that platelet aggregation and ADA activity could serve as peripheral markers for the development of effective therapy in the maintenance of homeostasis and some inflammatory process in these pathophysiological conditions. Copyright © 2016 John Wiley & Sons, Ltd.